脑脊液NPTX2预测从认知正常向轻度认知障碍的进展
本研究在269名认知正常的BIOCARD研究参与者中,探讨脑脊液突触蛋白NPTX2基线水平是否可预测轻度认知障碍(MCI)症状出现时间,并分析其与传统阿尔茨海默病(AD)脑脊液生物标志物的关系。结果显示,较低的基线NPTX2水平与较早的MCI症状出现时间相关(HR=0.76,SE=0.09,p=0.023),且在考虑基线AD生物标志物水平后仍能改善预测(p<0.01)。NPTX2可能是在临床前AD阶段有价值的预后生物标志物。
要点
- 在认知正常人群中,较低的脑脊液NPTX2基线水平与较早出现MCI症状相关(HR=0.76,p=0.023)。
- NPTX2在考虑基线AD生物标志物后仍能改善对MCI症状出现时间的预测(p<0.01)。
- 较高的基线p-tau181和t-tau水平与较高的基线NPTX2水平及更快的NPTX2下降速率相关(均p<0.001)。
核心结论
- NPTX2可能是临床前AD阶段有价值的预后生物标志物,在认知正常个体中对MCI发病提供附加且独立的预测。
- 作者假设NPTX2介导的回路稳态在AD早期阶段提供韧性。
研究设计与样本
- 纵向队列研究,纳入269名认知正常的BIOCARD研究参与者,基线平均年龄57.7岁,平均随访16.3年,其中77名进展为MCI/痴呆。
- 脑脊液纵向采集,使用定量平行反应监测质谱法从3种相关肽段测量NPTX2水平,使用Lumipulse自动电化学发光分析法测量Aβ42/Aβ40、p-tau181和t-tau水平。
主要发现
- 在Cox回归模型中,较低的基线NPTX2水平与较早的MCI症状出现时间相关(HR=0.76,SE=0.09,p=0.023)。
- 该关联在基线后7年内进展(p=0.036)和基线后7年后进展(p=0.001)中均显著。
- 在考虑基线AD生物标志物水平后,基线NPTX2水平改善了对MCI症状出现时间的预测(p<0.01),且NPTX2与脑脊液AD生物标志物或APOE-ε4基因状态无交互作用。
- 在线性混合效应模型中,较高的基线p-tau181和t-tau水平与较高的基线NPTX2水平相关(均p<0.001),并与NPTX2随时间下降速率更大相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study examined whether cerebrospinal fluid (CSF) baseline levels of the synaptic protein NPTX2 predict time to onset of symptoms of mild cognitive impairment (MCI), both alone and when accounting for traditional CSF Alzheimer's disease (AD) biomarker levels. Longitudinal NPTX2 levels were also examined. METHODS: CSF was collected longitudinally from 269 cognitively normal BIOCARD Study participants (mean baseline age = 57.7 years; mean follow-up = 16.3 years; n = 77 progressed to MCI/dementia). NPTX2 levels were measured from 3 correlated peptides using quantitative parallel reaction monitoring mass spectrometry. Levels of Aβ42 /Aβ40 , p-tau181 , and t-tau were measured from the same CSF specimens using Lumipulse automated electrochemiluminescence assays. RESULTS: In Cox regression models, lower baseline NPTX2 levels were associated with an earlier time to MCI symptom onset (hazard ratio [HR] = 0.76, SE = 0.09, p = 0.023). This association was significant for progression within 7 years (p = 0.036) and after 7 years from baseline (p = 0.001). Baseline NPTX2 levels improved prediction of time to MCI symptom onset after accounting for baseline AD biomarker levels (p < 0.01), and NPTX2 did not interact with the CSF AD biomarkers or APOE-ε4 genetic status. In linear mixed effects models, higher baseline p-tau181 and t-tau levels were associated with higher baseline levels of NPTX2 (both p < 0.001) and greater rates of NPTX2 declines over time. INTERPRETATION: NPTX2 may be a valuable prognostic biomarker during preclinical AD that provides additive and independent prediction of MCI onset among individuals who are cognitively normal. We hypothesize that NPTX2-mediated circuit homeostasis confers resilience during the early phase of AD. ANN NEUROL 2023;94:620-631.
引用
- Soldan A, Oh S, Ryu T, et al. NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment. Ann Neurol. 2023. PMID: 37345460. doi:10.1002/ana.26725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。